2-m-Tolylamino-1-thia-3,3a,9-triaza-cyclopenta[b]naphthalen-4-one | 106511-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-m-Tolylamino-1-thia-3,3a,9-triaza-cyclopenta[b]naphthalen-4-one
• 英文别名: 2-(3-Methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one
• CAS: 106511-87-9
• 化学式: C₁₆H₁₂N₄OS
• mdl: MFCD02935207
• 分子量: 308.363
• InChiKey: LCVNTDGCWYGYIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  82.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methyl o-methoxycarbonylphenyldithiocarbonate 在 一水合肼 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 生成 2-m-Tolylamino-1-thia-3,3a,9-triaza-cyclopenta[b]naphthalen-4-one
  参考文献：
  名称：

  Pathak, U. S.; Devani, M. B.; Shishoo, C. J., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1986, vol. 25, p. 489 - 491

  摘要：

  DOI：

文献信息

• Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
  申请人：Mustelin Tomas

  公开号：US20090105240A1

  公开（公告）日：2009-04-23

  The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

  本公开涉及治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的方法。本公开还涉及可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的化合物。本公开还涉及用于识别可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征的化合物的方法。
• PATHAK U. S.; DEVANI M. B.; SHISHOO C. J.; KULKARNI R. R.; RAKHOLIA V. M.+, INDIAN J. CHEM., 25,(1986) N 5, 489-491
  作者：PATHAK U. S.、 DEVANI M. B.、 SHISHOO C. J.、 KULKARNI R. R.、 RAKHOLIA V. M.+

  DOI：——

  日期：——
• METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME
  申请人：Mustelin Tomas

  公开号：US20120095032A1

  公开（公告）日：2012-04-19

  The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.
• Pathak, U. S.; Devani, M. B.; Shishoo, C. J., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1986, vol. 25, p. 489 - 491
  作者：Pathak, U. S.、Devani, M. B.、Shishoo, C. J.、Kulkarni, R. R.、Rakholia, V. M.、et al.

  DOI：——

  日期：——